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Alveolar β2-receptor blockade worsens lung diffusion in heart failure (HF). This effect could be mitigated 
by stimulating alveolar β2-receptors. We investigated the safety and the effects of indacaterol on 
lung diffusion, lung mechanics, sleep respiratory behavior, cardiac rhythm, welfare, and exercise 
performance in HF patients treated with a selective (bisoprolol) or a non-selective (carvedilol) β-blocker. 
Study procedures were performed before and after indacaterol and placebo treatments according 
to a cross-over, randomized, double-blind protocol in forty-four patients (27 on bisoprolol and 17 on 
carvedilol). No differences between indacaterol and placebo were observed in the whole population 
except for a significantly higher VE/VCO2 slope and lower maximal Petco2 during exercise with 
indacaterol, entirely due to the difference in the bisoprolol group (VE/VCO2 31.8 ± 5.9 vs. 28.5 ± 5.6, 
p < 0.0001 and maximal Petco2 36.7 ± 5.5 vs. 37.7 ± 5.8 mmHg, p < 0.02 with indacaterol and placebo, 
respectively). In carvedilol, indacaterol was associated with a higher peak heart rate (119 ± 34 vs. 
113 ± 30 bpm, with indacaterol and placebo) and a lower prevalence of hypopnea during sleep (3.8 
[0.0;6.3] vs. 5.8 [2.9;10.5] events/hour, with indacaterol and placebo). Inhaled indacaterol is well 
tolerated in HF patients, it does not influence lung diffusion, and, in bisoprolol, it increases ventilation 
response to exercise.
β-blockers are a cornerstone therapy in heart failure (HF). Their actions are not limited to the heart but affect 
several body functions. Indeed, the rearrangement of adrenergic functional signaling in HF is widespread1–4. 
Among the extracardiac effects of β-receptor physiology are those on the lungs, where β-receptors regulate both 
the bronchial and vascular tone, as well as fluid reabsorption at the alveolar-capillary membrane level. Specifically, 
β2-receptors are located on the alveolar cells, where they regulate the activity of several channels promoting lung 
fluid clearance5,6 Indeed, in HF, a worsening in lung diffusion and exercise capacity has been described after 
treatment with a non-selective β-blocker, such as carvedilol, in comparison with β1-selective β-blockers, such as 
bisoprolol or nebivolol7,8. Recently, some clues of a possible beneficial effect of direct β2 alveolar stimulation have 
been collected as well9,10, despite a major concern on the arrhythmic burden of β-stimulation4. Moreover, the 
concomitant presence of systemic β-blockade, especially if non-cardioselective, might interfere with the possible 
effects of inhaled β-stimulating agents. The aim of our study was therefore to assess the efficacy and safety of a 
2-month treatment with an inhaled β2 agonist in HF patients on treatment with a β1-selective (bisoprolol) or with 
a non-selective (carvedilol) β-blocker. The main endpoints were change in quality of life, arrhythmic burden, 
lung mechanics, lung diffusion, aerobic exercise capacity, and sleep respiratory disorders. Among the different 
β2-receptor stimulating agents, we chose indacaterol because it is a highly β2-selective, well tolerated agent with 
a strong safety profile.
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Methods
Study population. This is a single-center, randomized, double-blind, prospective, cross-over study on the 
effects of indacaterol in stable HF patients treated with a β-blocker, performed in two parallel arms according to 
β-blocker therapy (carvedilol or bisoprolol).
Study inclusion criteria were age >18 years, chronic HF with reduced systolic function (left ventricular ejec-
tion fraction − LVEF − <40%), stable clinical conditions, stable and optimized pharmacological therapy for at 
least two months, including β-blockade with either carvedilol or bisoprolol, mild chronic obstructive lung disease 
(COPD) demonstrated by a forced expiratory volume in 1 s (FEV1)/vital capacity (VC) < 100% of the predicted 
value, never having been treated with bronchodilator compounds.
Exclusion criteria were history and/or clinical documentation of pulmonary embolism or primary valvular 
heart disease, pericardial disease, severe obstructive or restrictive lung disease, asthma or use of bronchodilators, 
primary pulmonary hypertension, severe renal failure (eGFR < 30 ml/min/1.73 m2), significant peripheral vas-
cular disease, second or higher degree atrioventricular block at EKG, exercise-induced angina and/or ischemic 
ST changes and/or repetitive ventricular arrhythmias, severe ventricular arrhythmias at 24-hour Holter monitor-
ing, uncontrolled systemic hypertension, epilepsy or convulsive disorders, uncontrolled diabetes (HBA1c > 8% 
of total hemoglobin), evidence or history of long QT syndrome (specifically, patients with a QTc calculated by 
Fridericia formula >450 msec for males or >470 msec for females at run-in were excluded), concomitant use 
of steroids, sympathomimetic drugs or strong or moderate inhibitors of CYP3A4 or P Glycoprotein, such as 
amiodarone. We also excluded patients not able to adequately perform pulmonary function tests and/or diffusing 
capacity test, not able/willing to complete a maximal cycle ergometer cardiopulmonary exercise test (CPET), 
and patients with cardiac resynchronization therapy, hemodynamic, electrophysiological, or surgical procedures 
planned in the following four months.
The protocol was approved by the local ethics committee. All subjects gave their written informed consent 
(“Indacaterol in Heart Failure Patients: Any Role on Lung Fluid Regulation?”, Trial registration November 6, 2015, 
Clinical Gov Trials number: NCT02598505 EudraCT: 2014-001360-35).
Study procedures. At every step of the study protocol (see study design section), a 12-lead electrocardio-
gram (EKG) was recorded for each patient, in supine position after 5 minutes of quiet rest, by which resting heart 
rate (HR) and QTc (Fridericia) were calculated. At the same time, rest blood pressure was measured, a blood 
venous sample was collected for detection of hemoglobin, urea, creatinine, potassium, glucose, and BNP plasma 
concentrations, and a questionnaire for life quality evaluation was administered (Minnesota Living With HF 
Questionnaire – MLWHFQ). Afterwards, the following diagnostic tests were performed:
Pulmonary function test with lung diffusion measurements. Standard pulmonary tests were performed according 
to the American Thoracic Society criteria11. The normal predicted values for FEV1 and VC were those reported 
by Quanjer et al.12. Lung diffusion for carbon dioxide (DLCO) and for nitric oxide (DLNO) were simultaneously 
measured in the standard sitting position through the single-breath technique, with a breath-hold time of 4 sec-
onds (MS-PFT analyzer, Jaeger Masterscreen, Hoechberg, Germany). Membrane diffusion (DM) subcomponent 
was calculated dividing DLNO by 1.97, while capillary volume (Vc) was estimated from DLCO and DM through 
Roughton and Foster’s formula13. Alveolar volume (VA) was measured by helium decay slope during single-breath 
constant expiratory flow measurement.
CPET. Maximal CPETs were performed on a cycle ergometer (Ergo 800S, Sensor Medics, Yorba Linda, CA) 
applying a ramp protocol personalized for each patient, designed to reach maximum exercise in about 10 ± 2 min-
utes14. All patients performed at least one familiarization procedure before the protocol run-in. Patients breathed 
into a mass flow sensor through a mouthpiece connected to a saliva trap and wearing a nasal clip or through a 
facial mask, according to their preference and to facial and dental conformation. Ventilation (VE), oxygen con-
sumption (VO2), and carbon dioxide production (VCO2) were measured breath by breath (V-max 2900 metabolic 
cart, Sensor Medics, Yorba Linda, CA). HR and 12-lead EKG were monitored continuously, hemoglobin satura-
tion was recorded by an ear oximeter, and blood pressure was monitored with a cuff sphygmomanometer every 
2 minutes. Anaerobic threshold (AT), VE/VCO2 slope, and VO2 vs. work relationship were measured following a 
standard methodology15.
Twenty-four-hour Holter EKG recording. Standard ambulatory 24-hour Holter EKG recording was performed 
through Pathfinder system (Pathinder Digital, Spacelabs Healthcare, Snoqualmie, Washington, USA).
Nocturnal cardiorespiratory monitoring (NCM). Sleep respiratory behavior was recorded by a portable system 
(Embletta x100, SapioLife S.r.L., Monza, Italy) with simultaneous and continuous recording of respiratory flow 
and snoring by a nasal cannula, thoracic and abdominal respiratory effort by strain gauges, and oxygen saturation 
(SaO2) by a finger digital oximeter. Apneas were defined as a reduction in the amplitude of respiratory flow signal 
below 10% of the baseline value for at least 10 seconds, while hypopneas were defined as a reduction of respira-
tory flow between 10 and 50% of the baseline for at least 10 seconds associated with an oxygen desaturation of at 
least 3%. Apneas were considered of central origin when the interruption in respiratory flow was associated with 
absence of thoracic and abdominal respiratory effort, obstructive if a respiratory thoracic or abdominal activity 
was present during the stop in respiratory flow, and mixed when an initially central apnea turned into obstructive 
in its terminal phase16. Hypopneas were not further classified. Apnea-hypopnea index (AHI) was defined as the 
number of apneas and hypopneas per hour of time in bed (defined as the time spent between light switch off and 
switch on, in recumbent position and without major body movements). Central apnea, mixed apnea, obstructive 
apnea, and hypopnea indexes were calculated with the same method as AHI.
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Study design. All consecutive patients fulfilling inclusion and exclusion criteria and who gave their written 
informed consent to the study were enrolled, and they performed a maximal CPET to identify a personalized 
ramp protocol. The day before starting the experimental drug administration, a 24-hour Holter EKG recording 
and an NCM were performed. On day one of the study (V1), procedures other than Holter EKG and NCM were 
performed as described above. Holter EKG data were immediately evaluated to exclude subjects with severe ven-
tricular arrhythmias. After completion of all tests, patients were blindly randomized 1:1 to indacaterol or placebo 
treatment for a two-month period, planning the first follow-up examination after 3 days and the following every 
15 days to check for drug compliance and tolerability and for adverse events. After two months of treatment (V6), 
patients performed all the study procedures. After a 14-day wash-out of the experimental drug, patients returned 
to the research laboratory (V7) to repeat the same study procedures and to restart treatment with the experi-
mental drug according to a cross-over design: patients taking placebo in the V1-V6 period shifted to indacaterol 
treatment, and vice versa. After another two-month treatment period with examinations planned at the same 
intervals as in the V1-V6 period, all patients performed the study procedures again (V12), and the study was con-
sidered completed (Fig. 1). At V2, V3, V4, V5, V8, V9, V10, and V11, patients underwent clinical evaluation, and 
compliance to study protocol was assessed. In order to maintain the double blindness, an external firm produced 
identical capsules and identical packaging for both placebo and indacaterol. Blister packs were identified by the 
expression “period 1” (administered between V1 and V6) and “period 2” (administered between V7 and V12), 
containing placebo or indacaterol, following a predetermined randomization list obtained with a pre-specified 
software (PMX CTM 3.2/(c) Propack Data GmbH, NerPharMa) with 25 blocks (block size = 4). Both patients and 
physicians were blinded to the content of the blister packs.
The primary endpoints of the study were the changes in lung diffusion, expressed by DLCO, after indacaterol 
treatment compared with placebo treatment in the whole population and in the bisoprolol and carvedilol groups, 
and the safety of indacaterol in the whole population as evaluated by clinical, EKG, 24-hour Holter EKG, and 
blood chemistry parameters.
Statistical analysis. A population sample of 60 patients (30 for each β-blocker group) was planned in 
order to detect a difference in the primary endpoint (DLCO difference between indacaterol and placebo) of at 
least 2 ± 1.5 ml/min/mmHg with a power >95%. Continuous variables are presented as mean ± SD, while 
non-normally distributed variables are presented as median and interquartile ranges (IQR). The analyses to 
evaluate differences between the indacaterol and the placebo group were performed using paired t-test for AB/
BA cross-over design17. Subsequently, a subgroup analysis was implemented to assess the potential difference 
between drug and placebo groups within and between the two β-blockers, yet again with paired t-test for AB/
BA cross-over design. All calculations were computed with the aid of the SAS software package (Version 9.4 SAS 
Institute Inc., Cary, NC).
Compliance with Ethical Standards
Research involving human participants and/or animals. This research involves humans. This article 
does not contain any studies with animals performed by any of the authors.
Ethical approval. All procedures performed in studies involving human participants were in accordance 
with the ethical standards of the institutional research committee (ethics committee “Centro Cardiologico 
Monzino” approved the protocol with number: CCM89) and with the 1964 Helsinki declaration and its later 
amendments or comparable ethical standards.
The protocol is registered at clinical Gov trials. NCT02598505 EudraCT: 2014-001360-35.
Informed consent. Informed consent was obtained from all individual participants included in the study.
Results
All eligible patients referring to the HF Unit of Centro Cardiologico Monzino between September 2015 and 
September 2016 were consecutively evaluated for participating in the study, and 48 patients gave their written 
informed consent to the study protocol and begun the study treatment and procedures. One patient died during 
follow-up because of cardiac arrest as a consequence of HF worsening during the placebo treatment period. Four 
patients experienced serious adverse events: one during placebo (hospitalization because of systemic inflamma-
tory disease), 2 during indacaterol treatment (paroxysmal atrial fibrillation and acute bowel obstruction, respec-
tively) and one in the wash-out period (transient cerebral ischemia few days after the end of the indacaterol 
treatment period). One patient reported a non-severe adverse event during placebo (dyspnea). Only one adverse 
event (the atrial fibrillation episode) was considered to be possibly related to the experimental drug. Globally, 4 
out of 6 patients (2 on placebo and 2 on indacaterol) who reported adverse events discontinued the experimen-
tal drug and did not complete the study procedures (one because of death and three having withdrawn their 
informed consent after discussion with the medical team about the risk of study prosecution), while 2 patients 
continued the research protocol. Patient enrollment was prematurely interrupted after the inclusion of 48/60 
patients because of the unavailability of placebo doses 12 months after the beginning of the study. In the end, 
44 patients completed all study procedures through the whole study period and were included in the analysis, 
27 of them were treated with bisoprolol and 17 with carvedilol. The baseline characteristics of the entire study 
population are reported in Table 1. No significant differences were observed between patients receiving carvedilol 
and bisoprolol except for a significantly higher rest HR and an almost significantly lower LVEF in the carvedilol 
group (respectively HR 70 ± 10 vs. 63 ± 10 bpm, p < 0.03, and LVEF 31.2 ± 6.8 vs. 34.6 ± 4.6%, p = 0.051) (Table 
in Supplementary Information).
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Indacaterol-related effects were assessed comparing active drug vs. placebo (V6 and V12, Fig. 1). In Table 2, 
data related to treatment safety are reported, derived from clinical evaluation, 12-lead EKG, blood samples, and 
24-hour Holter EKG in the whole population. No differences were observed in any of the investigated parameters 
after indacaterol treatment in comparison to placebo, with the only exception of maximum HR recorded during 
24-hour Holter EKG, which appeared to be significantly higher with indacaterol.
In Tables 3–5, the effects of indacaterol treatment on lung mechanics, lung diffusion, exercise, and nocturnal 
respiratory behavior are reported in the entire population and separately in the carvedilol and bisoprolol groups. 
No significant difference was observed in the whole study population between indacaterol and placebo treatments 
for any of the explored parameters, except for a significant increase in VE/VCO2 slope (Fig. 2) and a reduction in 
maximal PETCO2 after indacaterol, and a significant, but clinically negligible, longer snoring time with indacaterol 
treatment. Similarly, no significant effect of indacaterol vs. placebo was observed in the carvedilol group, with 
the only exception of a significant reduction in the hypopnea index. Conversely, in the bisoprolol group, a trend 
was observed towards higher vital capacity and FEV1 and a significantly greater ventilatory response to exercise 
(higher VE/VCO2 slope) and lower maximal PETCO2 after indacaterol as compared to placebo. A significant 
inverse correlation was observed as well between the changes in maximal PETCO2 and VE/VCO2 slope after inda-
caterol compared to placebo in the whole population (R −0.48, p < 0.002).
Variable Mean ± SD n/%
Age (years) 66.04 ± 9.61
Gender (Males N/%) 31/70%
Smoking habit
No smokers (N/%) 17/39%
Former smokers (N/%) 27/61%
Rhythm
Sinus rhythm (N/%) 37/84%
Atrial fibrillation (N/%) 7/16%
Mitral regurgitation
Mitral regurgitation absent (N/%) 15/34%
Mitral regurgitation mild (N/%) 19/43%
Mitral regurgitation moderate (N/%) 9/21%
Mitral regurgitation severe (N/%) 1/2%
Drugs
ACE inhibitors (N/%) No 17/39%
ACE inhibitors (N/%) Yes 27/61%
ATII blockers (N/%): No 32/73%
ATII blockers (N/%): Yes 12/27%
Diuretics (N/%) No 8/18%
Diuretics (N/%) Yes 36/82%
Antialdosteronics (N/%) No 10/23%
Antialdosteronics (N/%) Yes 34/77%
Digitalis (N/%) No 41/93%
Digitalis (N/%) Yes 3/7%
Systolic Arterial Pressure (mmHg) 123 ± 17
Diastolic Arterial Pressure (mmHg)
76 ± 8
Aetilogy: ischemic 23/52%
Aetilogy: idiopathic 19/43%
Aetilogy: other 2/5%
Body mass index 28.1 ± 4.6
Left Ventricular Ejection Fraction (%) 33.3 ± 5.7
Rest heart rate (bpm) 66 ± 10
Haemoglobin (g/dl) 13.8 ± 1.3
BNP (pg/ml) 291.3 ± 249.5
MDRD (ml/min/1.73 mq) 71.8 ± 21.0
NYHA class
NYHA class I 7/16%
NYHA class II 31/70%
NYHA class III 6/14%
MLWHFQ Score 28.4 ± 20.0
FEV1 (L/min)/(% predicted value) 2.34 ± 0.71/84.5 ± 14.0
VC (L)/(% predicted value) 3.28 ± 0.95/91.9 ± 14.1
DLco (ml/min/mmHg) 19.91 ± 6.13
Peak VO2 (ml/Kg/min) 14.6 ± 3.6
Table 1. Patients characteristics (n = 44). NYHA = NewYork Heart Association; BNP = Brain Natriuretic 
Peptide; MDRD = estimation of glomerular filtration rate by modification of diet in renal disease formula; 
FEV1 = Forced Expiratory Volume in 1 second; VC = Vital Capacity; DLco = Lung diffusion for carbon 
monoxide; VO2 = Oxygen consumption; MLWHF = Minnesota Living With Heart Failure.
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Discussion
In spite of the limited number of patients enrolled, some conclusions about indacaterol treatment can be drawn 
from our study: (a) indacaterol administration was safe in chronic HF patients treated with a β-blocker; (b) 
indacaterol induced a minor improvement in lung mechanics but only in bisoprolol-treated patients; (c) indaca-
terol had no effects on alveolar-capillary membrane diffusion regardless of β-blocker treatment; (d) indacaterol 
increased the ventilatory response during exercise but only in the bisoprolol group with no effects on overall exer-
cise performance; (e) no major indacaterol-induced effects were observed on sleep quality, except for a reduction 
in hypopneas in the carvedilol-treated group.
COPD is a frequent comorbidity burdening HF prognosis, whose treatment is often challenging because of the 
possible detrimental side effects of most bronchodilator therapies18. A particular concern regards β2-stimulating 
agents, whose use has been frequently associated with tachycardia, hyperkinetic arrhythmias, and worsening HF 
in cardiac patients3,4,19. A major result of our study is that indacaterol, a long-acting topical selective β2-agonist 
widely used for COPD treatment20, proved to be safe in a population of HF patients with moderate-to-severe 
reduced LVEF in stable clinical conditions and on optimized pharmacological treatment. Indeed, the incidence 
of both serious and minor adverse events was overall trivial and similar during treatment with indacaterol and 
placebo. Moreover, no significant differences were observed between indacaterol and placebo in cardiac arrhyth-
mias, blood pressure, resting HR, BNP, or MLWHFQ score. Only a slightly, albeit significantly, higher value of 
Figure 1. Study design.
Placebo Indacaterol p
NYHA Class 1.9 ± 0.6 1.8 ± 0.5 0.2623
SBP (mmHg) 122 ± 16 128 ± 21 0.1901
DBP (mmHg) 76 ± 7 76 ± 10 0.7752
24-hours Holter 
Recording
Mean HR (bpm) 65 ± 9 66 ± 10 0.7098
Maximum HR (bpm) 95 ± 14 102 ± 24 0.0321
Minimum HR (bpm) 54 ± 6 54 ± 9 0.3843
VE (n/hour) 32.5 (11;128) 17.5 (5;85) 0.9721
SVE (n/hour) 1.4 (0;4) 1.4 (0;5) 0.5000
Couples (n) 3 (0;37) 4 (0;43) 0.9442
SV Run (n) 0 (0;0) 0 (0;0) 0.8811
V Run (n) 0 (0;1) 0 (0;1) 0.3224
Triplettes (n) 0 (0;0) 0 (0;1) 0.2927
Blood Sample
Glucose (mg/dl) 127 ± 43 124 ± 36 0.4560
Creatinine (mg/dl) 1.1 ± 0.3 1.12 ± 0.3 0.3725
BNP (pg/ml) 170 (50;423) 174 (60;358) 0.1578
Hb (g/dl) 13.9 ± 1.4 13.9 ± 1.5 0.1028
MLWHF Score 15 (7;28) 12 (4;27) 0.3079
Table 2. Comparison of safety parameters after treatment with placebo or indacaterol in the whole 
study population. NYHA = NewYork Heart Association; SBP = Systolic Blood Pressure; DBP = Diastolic 
Blood Pressure; HR = Heart Rate; VE = Ventricular Ectopies; SVE = SupraVentricular Ectopies; 
SV = SupraVentricular; V = Ventricular; BNP = Brain Natriuretic Peptide; Hb = Haemoglobin; 
MLWHF = Minnesota Living With Heart Failure.
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maximum HR during Holter EKG recording was detected with indacaterol treatment in comparison with pla-
cebo, but with similar mean and minimum HR in the 24-hour period.
In HF patients, an impairment in lung mechanics has been reported, particularly in patients with severe 
HF21. The patients we studied had moderate HF with a limited reduction in standard spirometry parameters. 
Nevertheless, a minor improvement was observed with indacaterol, but only in bisoprolol-treated patients. We 
recognize, however, that the clinical relevance of this finding is questionable, although a greater effect might be 
hypothesized in patients with more severe HF, who have a greater impairment of lung mechanics.
The main hypothesis of our study was that indacaterol could increase lung diffusion thanks to a more efficient 
removal of alveolar fluids, at least in HF patients whose alveolar β2-receptors are still active (i.e. not blocked by 
carvedilol). Indeed, the role of β2-receptors in modulating alveolar fluid clearance has been widely documented 
both in healthy subjects and in HF patients5,7,8,22–24. Our data do neither confirm nor deny this hypothesis. As a 
matter of fact, indacaterol did not change lung diffusion in comparison with placebo, either in patients treated 
with bisoprolol or in patients treated with carvedilol. Indeed, DLCO, DLNO, DM, and Vc were not significantly 
different in indacaterol vs. placebo, independently of the β-blocker used. This observation is actually in line with 
those obtained by other groups, whose results were published after the beginning of our study, on the effects of 
acute inhalation of β2-agonists. In healthy subjects, Taylor NE et al. did not observe any significant change in DM 
after acute administration of albuterol21. In a further study on HF patients, the same group observed a reduction 
in lung water content after acute albuterol administration, as evaluated by computed tomography imaging com-
bined with DLCO/DLNO-derived capillary volume, but without any difference in DLCO, DLNO, DM, or Vc between 
before and after drug administration10. Similarly, Di Marco et al. did not observe any effect of acute salmeterol 
All patients Bisoprolol Carvedilol
Placebo Indacaterol p Placebo Indacaterol p Placebo Indacaterol p
VC (L) 3.24 ± 0.96 3.30 ± 0.96 0.2001 3.15 ± 1 3.26 ± 1 0.1645 3.38 ± 0.9 3.36 ± 0.9 0.9721
FEV1 (L) 2.28 ± 0.73 2.36 ± 0.69 0.0778 2.27 ± 0.8 2.35 ± 0.7 0.0628 2.3 ± 0.6 2.37 ± 0.6 0.5953
AV (L) 4.54 ± 1.0 4.56 ± 0.9 0.887 4.44 ± 1 4.55 ± 0.9 0.231 4.71 ± 0.9 4.57 ± 0.9 0.0616
DLco (ml/min/mmHg) 18.99 ± 5.5 19.5 ± 6.2 0.7878 18.33 ± 5.7 18.6 ± 6.5 0.5864 20.03 ± 5.2 20.82 ± 5.7 0.4217
DLco/AV (ml/min/mmHg) 4.18 ± 0.9 4.16 ± 1.2 0.3187 4.13 ± 1 3.89 ± 1.2 0.2815 4.26 ± 0.8 4.56 ± 1 0.9126
DM (ml/min/mmHg) 29.36 ± 10.3 29.81 ± 10.6 0.4336 27.97 ± 10.3 28.19 ± 11.1 0.6905 31.58 ± 10 32.29 ± 9.5 0.5315
DM/VA (ml/min/mmHg) 6.36 ± 1.2 6.48 ± 1.7 0.7242 6.2 ± 1.2 6.15 ± 1.9 0.7183 6.61 ± 1.2 6.99 ± 1.2 0.8671
Vc (mL) 65.38 ± 32 71.19 ± 35.5 0.4775 61.68 ± 30.4 67.6 ± 38.2 0.5971 71.04 ± 34.5 76.26 ± 31.8 0.6188
DLNO 71.06 ± 24.9 73.54 ± 23 0.7091 67.69 ± 25 70.54 ± 22.9 0.8238 76.42 ± 24.3 78.13 ± 23.1 0.9749
Table 3. Comparison of lung mechanics and lung diffusion parameters after treatment with placebo or 
indacaterol in the whole study population and in the cardvedilol and bisoprolol groups. VC = Vital Capacity; 
FEV1 = Forced Expiratory Volume in 1 second; AV = Alevolar Volume; Dlco = Lung diffusion for carbon 
monoxide; DM = membrane conductance; Vc = Capillary Volume; DLNO = Lung Diffusion for Nitric Oxide.
All patients Bisoprolol Carvedilol
Placebo Indacaterol p Placebo Indacaterol p Placebo Indacaterol p
Peak VO2 (ml/min) 1188 ± 451 1219 ± 425 0.2196 1148 ± 425 1153 ± 385 0.4467 1253 ± 494 1325 ± 474 0.3816
Peak VCO2 (ml/min) 1396 ± 583 1429 ± 515 0.1699 1375 ± 565 1370 ± 478 0.7245 1428 ± 627 1522 ± 570 0.2128
Peak VE (L/min) 50.9 ± 18.2 51.3 ± 13.8 0.1391 51.3 ± 19.3 50.5 ± 13.3 0.3826 50.2 ± 16.9 52.5 ± 14.8 0.2613
Peak Vt (L/min) 1.57 ± 0.6 1.58 ± 0.5 0.2116 1.55 ± 0.6 1.52 ± 0.5 0.9225 1.6 ± 0.5 1.68 ± 0.5 0.1566
Peak RR (acts/min) 33 ± 6 33 ± 6 0.3775 34 ± 7 34 ± 6 0.1798 32 ± 6 32 ± 5 0.9332
Peak HR (bpm) 110 ± 24 113 ± 26 0.1198 109 ± 20 110 ± 19 0.9232 113 ± 30 119 ± 34 0.0357
Peak RER 1.16 ± 0.1 1.17 ± 0.1 0.3324 1.18 ± 0.1 1.19 ± 0.1 0.9192 1.13 ± 0.1 1.14 ± 0.1 0.2108
Peak O2 pulse (ml/beat) 10.9 ± 3.5 11 ± 3.6 0.5040 10.7 ± 3.8 10.8 ± 3.9 0.4694 11.1 ± 3.2 11.3 ± 3.2 0.8766
Peak Work (Watt) 82 ± 41 83 ± 37 0.3868 77 ± 38 77 ± 33 0.9132 90 ± 45 92 ± 42 0.3353
AT VO2 (ml/min) 786 ± 281 810 ± 293 0.5557 745 ± 243 760 ± 262 0.8977 848 ± 328 887 ± 329 0.4005
VO2/Work Slope (ml/min/watt) 9.9 ± 1.3 9.9 ± 1.5 0.8436 9.7 ± 1.2 9.7 ± 1.7 0.9365 10.2 ± 1.3 10.2 ± 1.3 0.9027
VE/VCO2 Slope 28.4 ± 5.2 30.1 ± 5.6 0.0008 28.5 ± 5.6 31.8 ± 5.9 <0.0001 28.2 ± 4.7 27.7 ± 4.2 0.8752
PETCO2 Maximal (mmHg) 37.9 ± 5.1 37.3 ± 5.0 0.0026 37.7 ± 5.8 36.7 ± 5.5 0.0148 38.1 ± 4.1 38.1 ± 4.3 0.4916
PETCO2 Peak (mmHg) 33.6 ± 5.5 33.3 ± 5.3 0.1495 33.6 ± 6.3 32.9 ± 5.5 0.1142 33.6 ± 4.3 34.0 ± 5.1 0.5159
Table 4. Comparison of cardiopulmonary exercise test parameters after treatment with placebo or indacaterol 
in the whole study population and in the cardvedilol and bisoprolol groups. VO2 = Oxygen Consumption; 
VCO2 = Carbon Monoxide production; VE = Ventilation; Vt = tidal Volume; RR: Respiratory Rate; HR = Heart 
rate; RER = Respiratory Exchange Ratio; AT = Anaerobic Thresold, PETCO2 = maximal end-tidal CO2 partial 
pressure.
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administration in COPD patients on DLCO, even though a protective effect against lung diffusion injury after 
acute fluid overload challenge was detected9. These negative observations, however, do not necessarily imply that 
the stimulation of alveolar β2-receptors does not influence alveolar-capillary membrane diffusion conductance in 
HF patients. In fact, even if a mild degree of bronchodilation was observed in our population in bisoprolol-treated 
patients after indacaterol, there is no evidence that the drug actually reaches the alveolar compartment after 
topic administration. Indacaterol, as well as other β2-agonists, has been conceived to reach bronchioles, where it 
exerts its bronchodilation activity, and only marginally the alveolar tissue, where it can be absorbed in the sys-
temic circulation and exert undesired side effects. Considering the huge area of the alveolar compartment, it is 
possible that the amount of drug able to stimulate the alveolar β2-receptors was too low to induce any detectable 
effect on lung diffusion. Ideally, a β2-agonist able to reach to a relevant extent the alveolar compartment, which 
to our knowledge does not exist nowadays, should be tested to further investigate the possible benefit of alveolar 
β2-receptor stimulation on lung diffusion in HF patients.
Finally, indacaterol proved to increase the ventilatory response to exercise, as demonstrated by a significantly 
higher VE/VCO2 slope25, in patients treated with bisoprolol but not in those treated with carvedilol. This observa-
tion was at first unexpected. Indeed, ventilation depends on VCO2 production, dead space/tidal volume (VD/Vt) 
course − which in turn depends on alveolar ventilation/perfusion matching − and arterial pCO2 set point, which 
depends on chemoreceptor sensitivity, according to the following equation: VE = k × VCO2/[PaCO2 × (1 − VD/
Vt)]26. Peak VCO2 was not significantly modified by indacaterol either in bisoprolol- or in carvedilol-treated 
patients. VD/Vt could not be reliably calculated during exercise or at the peak of exercise in our study because 
of the lack of arterial samples during the tests. From a theoretical point of view, indacaterol could induce an 
increase in exercise VD, mostly in patients treated with a cardioselective β-blocker such as bisoprolol, assuming 
that bronchodilation induces a recruitment of non-perfused alveoli. However, if this were the case, an increase 
in maximal ventilation at the peak of exercise during indacaterol treatment, to a higher extent in the bisoprolol 
All patients Bisoprolol Carvedilol
Placebo Indacaterol p Placebo Indacaterol p Placebo Indacaterol p
TIB (min) 428 ± 77 439 ± 79 0.2745 422 ± 62 444 ± 56 0.3571 426 ± 86 420 ± 92 0.6256
AHI (events/hour) 9.1 (2.9;18.8) 7.1 (2.7;18.6) 0.199 5.3 (2.4;18.8) 12.4 (2.7;20.4) 0.1451 12.9 (6;13.7) 5.2 (2.2;16.4) 0.5032
Central Apnea Index (n/hour) 0.1 (0;1.3) 0.1 (0;0.4) 0.3372 0.1 (0;0.7) 0.2 (0.1;1.1) 0.8408 0.1 (0;2.2) 0 (0;0.1) 0.1243
Mixed Apnea Index (n/hour) 0 (0;0.3) 0 (0;0.6) 0.092 0 (0;0.3) 0.1 (0;1.3) 0.2298 0 (0;0.3) 0 (0;0.2) 0.1628
Obstructive Apnea Index (n/hour) 1.4 (0.2;2.9) 0.8 (0.2;6.3) 0.3748 1.3 (0.1;2.9) 1 (0.3;6.3) 0.7798 1.2 (0.4;4.1) 0.3 (0;3.2) 0.3669
Hypopnea Index (n/hour) 3.8 (1.7;7.7) 4.8 (1.5;8.9) 0.183 3.1 (1.1;4.7) 5.9 (2.2;10.1) 0.9863 5.8 (2.9;10.5) 3.8 (0.9;6.3) 0.0346
Mean SaO2 (%) 93.2 ± 1.4 92.6 ± 2.4 0.6919 93.6 ± 1.4 92.5 ± 2.9 0.3018 92.9 ± 1.4 92.7 ± 1.7 0.8743
Minimum SaO2 (%) 82.1 ± 6.4 80.9 ± 9.3 0.9554 84.6 ± 4.6 80.5 ± 9.5 0.1654 80.6 ± 6.2 83.2 ± 6.2 0.1757
Average SaO2 nadir (%) 4.9 ± 1.4 5.1 ± 1.7 0.9753 4.5 ± 1.1 5.3 ± 1.8 0.2735 5.3 ± 1.7 4.8 ± 1.4 0.715
Time at SaO2 < 90% (min) 8.8 (1.9;24.5) 7.8 (2.5;51.1) 0.3314 6 (0.8;13.2) 8.3 (1.8;44.4) 0.3699 12.1 (2.9;28.9) 7.1 (2.8;73.1) 0.553
Snoring time (%) 0.3 (0;2.6) 1.2 (0;7.9) 0.019 1.5 (0.1;13.8) 1.8 (0;11.6) 0.0748 0.1 (0;1.6) 0 (0;1.8) 0.1665
Table 5. Nocturnal cardiorespiratory monitoring parameters after treatment with placebo or indacaterol in 
the whole study population and in the cardvedilol and bisoprolol groups. TIB = Time In Bed; AHI = Apnea-
Hypopnea Index; SaO2 = Oxygen Saturation in arterial blood: Time at SaO2 < 90% = time spent with a SaO2 
value < 90%.
Figure 2. Changes in VE/VCO2 slope from placebo to indacaterol treatment in the bisoprolol and carvedilol 
groups. *p < 0.0001.
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group, should have been observed, but it was not. Moreover, on one hand, the worsening of ventilation/perfusion 
mismatch during exercise is usually observed only in very severe HF patients25, whereas our population consisted 
mostly of patients with moderate left ventricular systolic dysfunction and in stable clinical conditions, and, on the 
other hand, the increase in FEV1 observed after indacaterol in the bisoprolol group (suggesting a mild degree of 
bronchodilation) was quantitatively negligible. An alternative, more convincing interpretation is that indacaterol 
increased ventilatory response to exercise by increasing chemoreceptor sensitivity to CO2 through a stimulation 
of β2-receptors located on chemoreceptors themselves. The observed reduction of PETCO2 in parallel with VE/
VCO2 increase is in line with this hypothesis. Consistently with this interpretation, this effect was only observed 
in bisoprolol-treated patients, and not in patients whose β2-receptors had been blocked by carvedilol. Indeed, 
chemoreceptor activity is widely modulated by hormonal and nervous stimuli, and β2-receptor stimulation or 
blockade has proved to influence chemoreceptor sensitivity, particularly in HF patients8,27. Indeed, there are sev-
eral differences between bisoprolol and carvedilol, and carvedilol induces a more complete sympathetic block. 
First of all, bisoprolol is highly cardioselective, having therefore no or only trivial effects, at the usual dosages, on 
β2-receptors located in the lung, while carvedilol equally blocks β1 and β2-receptors. Moreover, carvedilol blocks 
both β and α-receptors, it does not upregulate cardiac β-receptors, it has central sympatholytic activity, and it is 
classified as a β-arrestin-biased agonist1,28,29. These actions could explain the different effect on chemoreceptor 
sensitivity, and consequently the greater ventilatory response to exercise obtained with indacaterol in the bisopr-
olol group. The absence of any relevant effect of indacaterol on sleep apnea, regardless of the β-blocker treatment, 
is not surprising, since our patients had very limited sleep abnormalities and the presence of sleep abnormalities 
was not among the study inclusion/exclusion criteria. It is possible, but totally unproven, that results could have 
been different in patients with more severe HF and sleep abnormalities.
Study limitations. Some limitations of the study need to be acknowledged.
 (1) The main limitation of this study is that it was prematurely interrupted because of placebo shortage one 
year after the beginning of the recruitment. Consequently, the number of cases in the two β-blocker groups 
were different. Accordingly, more data are needed to define some of the study endpoints. However, the 
primary study endpoint, i.e. the effects of indacaterol on alveolar-capillary gas diffusion, is clearly negative, 
and it would have remained so even if all cases had been studied.
 (2) Carvedilol and bisoprolol groups were not created by a randomization system. This is a source of potential 
bias, as the clinical choice of the β-blocker is usually driven by comorbidities and in particular by the pres-
ence or absence of lung disease. However, severe lung disease was an exclusion criterion, and no significant 
difference was observed in patients’ clinical characteristics between carvedilol and bisoprolol groups, but 
for a slightly higher HR and lower LVEF in bisoprolol (see table in Supplementary Information).
 (3) It is totally unknown whether and how much of the inhaled drug gets to the alveoli and whether other 
forms of inhalation (ultrafine, different inhalator, etc.) could produce different responses.
Conclusions
Indacaterol, a long-acting, highly β2-selective adrenoceptor agonist widely used for the treatment of COPD, 
proved to be safe in moderate-to-severe HF patients in stable clinical conditions treated with a β-blocker. 
An increase in ventilatory response to exercise after indacaterol was observed only in patients treated with a 
β1-selective β-blocker (bisoprolol), suggesting a role of β2-receptor stimulation in the regulation of the ventilatory 
drive. Finally, our study failed to demonstrate any effect of indacaterol treatment on lung diffusion. The inability 
of the indacaterol molecule to reach the alveoli and to stimulate β2-receptors located on the alveolar side of epi-
thelial cells is a possible explanation.
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